Back

Stealth BioTherapeutics to Participate in Upcoming Investor Conferences

September 06, 2016

BOSTON – September 6, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Stealth Chief Executive Officer Reenie McCarthy will participate in three upcoming investor conferences.  Details are below:

  • Morgan Stanley Global Healthcare Conference. Members of the management team will participate in one-on-one meetings on Monday, September 12, 2016 in New York City.
  • Ladenburg Thalmann 2016 Healthcare Conference. A corporate overview will be presented at 10:00 a.m. ET on Tuesday, September 27, 2016 in New York City.
  • Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology. A corporate overview will be presented at 8:00 a.m. ET on Wednesday, September 28, 2016 in New York City.

Stealth BioTherapeutics: Leading Mitochondrial Medicine

Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondrial therapies to patients to treat both rare and common diseases. Stealth’s clinical development program is focused along several core therapeutic areas, including primary mitochondrial diseases, cardiorenal diseases and ophthalmic disorders. More information regarding Stealth and its pipeline is available at StealthBT.com.

Contact:

Media Relations
dna Communications

Taylor Ramsey
Phone: 617-520-7018
Media@StealthBT.com

 

Investor Relations
Stern IR

Beth DelGiacco
Phone: 212-362-1200

IR@StealthBT.com

Media Relations

dna Communications
Kate Contreras, 617-520-7088
media@stealthbt.com

Investor Inquiries
Stern IR
Rachel Frank, 212-362-1200
IR@stealthbt.com